Glyrx-pf Injection, Solution
NDC Package 51754-6000-4
Package Information
Glyrx-pf (glycopyrrolate) injection is glycopyrrolate solution is used to reduce excessive drooling caused by medical conditions (such as cerebral palsy). This formulation utilizes a injection, solution delivery system. Marketed by Exela Pharma Sciences, Llc, this product is identified by NDC 51754-6000 and is authorized under FDA application NDA210997.
Identification & Billing
- RxCUI: 1731582 - glycopyrrolate 0.2 MG in 1 ML Injection
- RxCUI: 1731582 - 1 ML glycopyrrolate 0.2 MG/ML Injection
- RxCUI: 1731582 - glycopyrrolate 0.2 MG per 1 ML Injection
- RxCUI: 1731590 - glycopyrrolate 0.4 MG in 2 ML Injection
- RxCUI: 1731590 - 2 ML glycopyrrolate 0.2 MG/ML Injection
Clinical Specifications
- Intramuscular - Administration within a muscle.
- Intravenous - Administration within or into a vein or veins.
Regulatory & Marketing
Hierarchy Structure
- 51754 - Exela Pharma Sciences, Llc
- 51754-6000 - Glyrx-pf
- 51754-6000-4 - 25 VIAL, SINGLE-DOSE in 1 CARTON / 1 mL in 1 VIAL, SINGLE-DOSE
- 51754-6000 - Glyrx-pf
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Billing & HCPCS Mapping
To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.
Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 51754-6000-4 identifies a specific commercial package of 25 vial, single-dose in 1 carton / 1 ml in 1 vial, single-dose of Glyrx-pf, a human prescription drug labeled by Exela Pharma Sciences, Llc. This injection, solution is formulated for intramuscular; intravenous use and contains glycopyrrolate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Exela Pharma Sciences, Llc on August 01, 2018. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Glycopyrrolate solution is used to reduce excessive drooling caused by medical conditions (such as cerebral palsy). This medication works by decreasing the amount of saliva you make. Glycopyrrolate belongs to a class of drugs known as anticholinergics.
How is this Exela Pharma Sciences, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 51754600004. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.
